Earnings call transcript: LENZ Therapeutics sees growth in Q1 2026 By Investing.com

LENZ Therapeutics reported Q1 2026 net revenue of $1.9 million, up with roughly 25,000 paid and filled prescriptions, a 19% quarter-over-quarter increase. The company ended the quarter with $258.4 million in cash and equivalents, though it still posted a $41.5 million net loss and $45 million of SG&A as the VIZZ launch scales. Shares rose 3.28% after hours as management highlighted DTC traction, expanding prescriber adoption, and continued commercial momentum.

Analysis

LENZ is transitioning from a pure launch story to a behavior-shift story, which is harder but more durable if it works. The key incremental signal is not the prescription count itself; it’s the rising share of repeat writers and 3-month orders, which suggests the product is starting to embed into practice workflows rather than relying on one-off sampling. That matters because once a prescriber changes habit, the marginal cost of volume falls and the launch becomes less dependent on headline advertising efficiency.

The near-term winner is likely not the broad ophthalmology complex, but adjacent channels that reduce friction: ePharmacy, direct-to-practice fulfillment, and any vendor tied to consumer onboarding. The second-order loser is the legacy presbyopia experience—readers and older miotic products—because LENZ is training doctors to introduce treatment earlier in the exam, which can suppress share even before total category demand fully expands. If the contact-lens angle scales, it effectively converts a retention problem for practices into a prescription driver, making LENZ more of a revenue-defense tool than a pure elective add-on.

The risk is that the market is extrapolating early engagement metrics into full funnel conversion too quickly. DTC awareness can improve fast, but prescription conversion typically lags by multiple quarters; if refill data in 2H does not confirm persistence, the stock will re-rate back toward a cash-burn narrative. The other key risk is competitive copycatting: if rivals keep sampling aggressively, LENZ may need to spend more just to defend share, compressing the implied operating leverage.

Contrarian take: the stock may still be cheap on cash, but not necessarily cheap on execution probability. The upside case depends on proving that repeat prescribing is a habit formation curve, not a sampling artifact; if that inflects, revenue can accelerate non-linearly in 2026. If it doesn’t, the balance sheet becomes a long-duration bridge to a slower adoption curve rather than a moat.

Key Decisions for Investors

• Long LENZ 3-6 months via starter position; add only if 2H refill disclosure confirms persistence and 3-month mix keeps rising. Risk/reward: asymmetric if repeat use is validated, but cut quickly if new-script growth stalls after DTC and field expansion.
• Buy LENZ call spreads into the next 1-2 earnings prints; structure for upside on a 2H adoption inflection while capping premium risk. Use strikes 20-30% above spot to avoid paying for a full commercialization rerate.
• Pair trade: long LENZ / short a basket of slower-growth ophthalmology names that rely on older treatment paradigms. Thesis is category creation and workflow embedding vs. legacy share maintenance.
• Avoid shorting LENZ outright despite the run-up; the cash position limits downside, and the next two quarters are likely to be catalyst-rich. If bearish, express it via put spreads after any post-print spike rather than naked short.
• Watch for a tactical entry after any dip tied to competitive sampling headlines or a delay in refill disclosure; those are likely better entry points than chasing strength after DTC-driven sentiment pops.